Trial
NCT02245412
A Phase 2A Study of ALXN1007 in Participants With Newly Diagnosed Acute Lower Gastrointestinal Graft-Versus-Host Disease
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Alexion Pharmaceuticals, Inc.
Collaborators
—
Condition
Acute Graft-Versus-Host Disease
Intervention
ALXN1007 10 mg/kg once weekly
Why stopped
Terminated early at the Sponsor's discretion, not due to safety concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-01-03